Method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 34.24% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTTravere Therapeutics, Inc.'s latest supported as-filed period reports revenue of $169.6M, 48.2% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 34.24% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 48.17% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 23.62% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 98.72% · CORE
Level · gp.fundamentals.operating_margin
Raw value 2.33% · CORE
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 12.85% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 48.2%; Operating margin moved 1338 bp higher; Operating income changed across a sign change.
3 evidence-backed componentsNet income changed -172.8% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Each point keeps the date investors could first observe it and its accession.
TVTX · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001943192-26-000005SEC ↗4Aug 19, 2026Period Aug 17, 20260001123343-26-000010SEC ↗10-QAug 4, 2026Period Jun 30, 20260001438533-26-000063SEC ↗8-KAug 4, 2026Period Aug 4, 20260001438533-26-000062SEC ↗8-KJul 9, 2026Period Jul 6, 20260001438533-26-000054SEC ↗4Jun 22, 2026Period Jun 22, 20260001902368-26-000007SEC ↗4Jun 16, 2026Period Jun 12, 20260001376043-26-000010SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 2, 2026Filed Sep 3, 2026 | Cline Christopher R.CHIEF FINANCIAL OFFICER | Open Market SaleDirect | 642 | $66 | $42,610 | Form 4 ↗ |
| Aug 18, 2026Filed Aug 19, 2026 | LYONS GARY ADirector | Option ExerciseDirect | 5,000 | $17 | $87,200 | Form 4 ↗ |
| Aug 18, 2026Filed Aug 19, 2026 | LYONS GARY ADirector | Open Market SaleDirect | 4,100 | $63 | $259,390 | Form 4 ↗ |
| Aug 18, 2026Filed Aug 19, 2026 | LYONS GARY ADirector | Open Market SaleDirect | 900 | $64 | $57,470 | Form 4 ↗ |
| Aug 18, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating margin changed +1338 basis points from the comparable as-filed period.
Revenue changed +48.2% from the comparable as-filed period.
Cash & equivalents changed +56.7% from the comparable as-filed period.
SBC / revenue changed +354 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Stock-based compensation changed +104.6% from the comparable as-filed period.
Selling, general & administrative changed +26.1% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001680739-26-000014| LYONS GARY ADirector |
| Option ExerciseDirect |
| 5,000 |
| $0 |
| $0 |
| Form 4 ↗ |
| Aug 17, 2026Filed Aug 19, 2026 | LYONS GARY ADirector | Option ExerciseDirect | 5,000 | $17 | $87,200 | Form 4 ↗ |
| Aug 17, 2026Filed Aug 19, 2026 | LYONS GARY ADirector | Open Market SaleDirect | 1,900 | $63 | $118,805 | Form 4 ↗ |
| Aug 17, 2026Filed Aug 19, 2026 | LYONS GARY ADirector | Open Market SaleDirect | 2,600 | $63 | $165,100 | Form 4 ↗ |
| Aug 17, 2026Filed Aug 19, 2026 | LYONS GARY ADirector | Open Market SaleDirect | 500 | $64 | $32,081 | Form 4 ↗ |
| Aug 17, 2026Filed Aug 19, 2026 | LYONS GARY ADirector | Option ExerciseDirect | 5,000 | $0 | $0 | Form 4 ↗ |